Physician profile
Edwin Okyne
NPI 1699221960
$535.37
in general payments reported to CMS, 2019-2025
10 companies · $26.84 in 2025
The $26.84 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2021: $94.86 · 2024: $156 · 2025: $26.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $149 · Education: $33.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $149.11 |
| Education | $33.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $257.47 | 2019 | |
| Novo Nordisk INC | $127.13 | 2021-2024 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.34 | 2024 | Jardiance |
| Daiichi Sankyo INC. | $25.18 | 2025 | Injectafer |
| Aurinia Pharma U.S., INC. | $23.60 | 2024 | Lupkynis |
| Exact Sciences Corporation | $21.16 | 2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $15.74 | 2024 | Voquezna |
| Lilly USA, LLC | $15.61 | 2024 | Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.48 | 2024 | Caplyta |
| Travere Therapeutics, INC. | $1.66 | 2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Okyne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.